Thyroid transcription factor 1 and p63 expression is associated with survival outcome in patients with non-small cell lung cancer treated with erlotinib
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F20%3A10412029" target="_blank" >RIV/00216208:11140/20:10412029 - isvavai.cz</a>
Alternative codes found
RIV/00669806:_____/20:10412029
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=pWiMG0leap" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=pWiMG0leap</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3892/ol.2020.11663" target="_blank" >10.3892/ol.2020.11663</a>
Alternative languages
Result language
angličtina
Original language name
Thyroid transcription factor 1 and p63 expression is associated with survival outcome in patients with non-small cell lung cancer treated with erlotinib
Original language description
Erlotinib is used mainly in patients with sensitizing EGFR mutations. In clinical practice, erlotinib is also used in non-mutated patients in higher lines of treatment. However, there is no predictive marker for efficacy of erlotinib in wild-type (wt) patients. Immunohistochemical (IHC) parameters such as the thyroid transcription factor 1 (TTF1) or p63 have been shown to possibly have the predictive power. When IHC parameters were ignored, our cohort of 679 patients showed the same efficacy of erlotinib in both squamous lung cancer and adenocarcinoma. However, we found significant differences in progression free survival (PFS) and overall survival (OS) in a subgroup of 126 patients where these parameters were known. In a univariate analysis, the group A (TTF1 positive and p63 negative adenocarcinomas) achieved PFS of 2.6 months, the group B (TTF1 negative and p63 positive squamous carcinomas) 1.9 months and the group C (did not fall into either A or B) 1.4 months (p = 0.006). Median OS was 14.2, 19.1 and 5.3 months for A, B and C, respectively (p = 0.002). A multivariate analysis then demonstrated IHC markers to be the only significant parameters for both PFS and OS. The group C was a negative prognostic factor for PFS (HR = 1.81, p = 0.02) and OS (HR = 2.37, p = 0.008). In conclusion, EGFR wt patients with lung carcinomas without the TTF1 and p63 expression typical for adenocarcinomas (ADC) and squamous cell carcinomas (SCC) do not appear to be suitable candidates for erlotinib treatment.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30203 - Respiratory systems
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Oncology Letters
ISSN
1792-1074
e-ISSN
—
Volume of the periodical
20
Issue of the periodical within the volume
2
Country of publishing house
GR - GREECE
Number of pages
7
Pages from-to
1376-1382
UT code for WoS article
000563832100043
EID of the result in the Scopus database
2-s2.0-85087210919